Health Catalyst Divests Vitalware for $147 Million to Accelerate AI Focus
HCAT•Health Catalyst will divest Vitalware for $147 million in cash to sharpen focus on its AI-driven technology and core healthcare intelligence offerings. The net proceeds, combined with cash on hand, will fully retire approximately $160 million of secured term loan debt, strengthening the balance sheet for future growth.
1. Divestiture Details
Health Catalyst signed a definitive agreement to sell Vitalware to Med-Metrix for $147 million in cash, subject to regulatory approvals, with closing expected in 2026.
2. Strategic Focus Shift
Proceeds are earmarked to reinforce the company’s AI roadmap and core healthcare intelligence platform, building on 18 years of proprietary data and $2.8 billion in documented outcomes.
3. Debt Repayment Plan
Health Catalyst plans to combine divestiture proceeds with existing cash to fully retire approximately $160 million of senior secured term loan principal plus related costs, bolstering its balance sheet.
4. Vitalware Business Transition
Vitalware, a best-in-KLAS mid-revenue cycle software suite generating about $37 million in fiscal 2025 revenue, will join Med-Metrix’s revenue cycle management services for deeper investment and growth.
